BMJ

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study

Correspondence to Dr Lea Hoisnard, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique - Hôpitaux de Paris, Paris, Île-de-France, France; ...
BMJ

HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis

10 Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK Correspondence to Dr Darren Plant, Centre for Musculoskeletal Research, ...
BMJ

Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study

1 Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands 2 Department of Rheumatology, Leiden University Medical Center, Leiden, The ...
BMJ

Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis

3 Centre de Recherche en Epidémiologie et Statistiques (CRESS), Unité Inserm 1153, Université Paris Cité, Paris, France ...
BMJ

Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

We read with interest the recent article by Singh and Cleveland on the hypersensitivity risk of allopurinol (ALP) and febuxostat (FBX) compared with colchicine.1 A common challenge when using ALP, ...
BMJ

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo ...

Objectives Rheumatoid arthritis (RA) has a considerable disease burden with life-long physical limitations, reduced work productivity and high societal costs. Trials on arthralgia at-risk for RA are ...
BMJ

Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...
BMJ

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness

Objective Considering the diverse aetiologies and immunodysregulatory statuses observed in each patient with rheumatoid arthritis (RA), stratification based on peripheral blood immunophenotyping holds ...
BMJ

OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial

Background Interleukin-23 (IL-23), a key regulator of multiple effector cytokines, has been implicated in the pathogenesis of psoriatic lesions, synovitis, enthesitis, and bone erosion. Risankizumab ...
BMJ

Correspondence on ‘Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial’

Correspondence to Xiaoqing Peng, Department of Obstetrics and Gynaecology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, China; pengxiaoqing{at}ahmu.edu.cn We read with ...
BMJ

EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part ...

33 Department of Paediatrics and Adolescent Medicine, Tbilisi Hospital #1 and Georgian Scientific-Practical Rheumatology Centre, Tblisi State Medical University, Tbilisi, Georgia 34 Dipartimento di ...
BMJ

Yet more evidence that osteoarthritis is not a cartilage disease

In this issue of the Annals of Rheumatic Diseases, Tan et al 1 report the results of high-resolution magnetic resonance imaging (hrMRI) of interphalangeal joints of 20 subjects who had “clinically ...